Key result
Glycoprotein IIb/IIIa inhibitors prevent platelet aggregation and exert further biological functions, though large-scale studies comparing their efficacy and safety are lacking.
Population
Patients subjected to percutaneous coronary intervention
Design
Review
Authors
Loading...
Potential pleiotropic effects of GPIIb/IIIa inhibitors remain hypothesis-generating; large comparative trials are needed to define any clinical role.
This review highlights the potential pleiotropic effects of GPIIb/IIIa antagonists beyond platelet aggregation, suggesting a possible role in vascular repair.
Giordano et al. (2016) conducted a review in percutaneous coronary intervention. Glycoprotein IIb/IIIa Antagonists was evaluated. Glycoprotein IIb/IIIa inhibitors prevent platelet aggregation and exert further biological functions, though large-scale studies comparing their efficacy and safety are lacking.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: